Patheon opens additional laboratory
Toronto, Canada-based Patheon has opened its newly constructed formulation development facility at its regional operations site. The 8,500 ft² addition to Patheon's manufacturing building represents investment of US$2m and includes two formulation development suites, eight pilot scale development suites capable of handling high and low potency molecules, as well as offices for the formulation scientists. They form part of the company's growing pharmaceutical development services business, which provides dosage form development services for new drugs in clinical trials.
During the past five years, revenues from Patheon's development services business have grown at an annual rate of 69%. In the fiscal year 2000, the company provided development services for more than 110 products, nine of which are nearing regulatory approval in preparation for commercial manufacturing.
'The completion of this new facility marks a significant milestone on the path to expanding our pharmaceutical development services globally,' said coo Nick DiPietro. 'Our focus is on providing integrated drug development and manufacturing services to our clients. These new premises will enable us to help our clients move products from development to commercialisation more quickly and cost-effectively.'